How should a low‑positive anti‑N‑methyl‑D‑aspartate receptor (anti‑NMDA‑R) antibody result (+1) be interpreted and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Low-Positive Anti-NMDAR Antibody (+1): Interpretation and Management

A low-positive anti-NMDAR antibody result (+1) in serum alone is clinically unreliable and should not drive treatment decisions—CSF testing is mandatory to establish the diagnosis of anti-NMDAR encephalitis, as serum antibodies are considered specific only when accompanied by CSF positivity.

Clinical Context Determines Everything

The interpretation hinges entirely on whether the patient meets clinical criteria for autoimmune encephalitis. Low-titer serum results are frequently false positives, particularly when testing is performed with low pre-test probability 1, 2.

Key Diagnostic Framework

CSF testing is non-negotiable for the following reasons:

  • CSF antibody testing has 100% sensitivity versus only 85.6% for serum 3
  • Serum-only positivity, especially at low titers, often represents clinically irrelevant findings 1
  • Commercial assays in non-reference laboratories demonstrate unexpectedly low serum sensitivity, making low-positive results even more suspect 4
  • A negative anti-NMDAR antibody-specific index (comparing CSF to serum) has a negative predictive value of 1.0 for ruling out true anti-NMDAR encephalitis 5

Management Algorithm

Step 1: Assess Clinical Probability

Does the patient have features suggesting autoimmune encephalitis?

Required criteria (all three) 6:

  • Acute/subacute onset (<12 weeks)
  • Evidence of CNS inflammation (CSF pleocytosis, oligoclonal bands, elevated IgG index, OR characteristic MRI findings such as mediotemporal FLAIR/T2 hyperintensities, OR inflammatory pathology)
  • Exclusion of infectious, toxic, metabolic, neoplastic, or other causes

High-risk clinical features for anti-NMDAR encephalitis specifically 7:

  • Prodromal cognitive deficits
  • Catatonia
  • Speech disturbance
  • Antipsychotic sensitivity
  • Progression to seizures, movement disorders, or autonomic instability

Step 2: Obtain CSF Testing Immediately

Do not delay CSF analysis 6. Test for:

  • Anti-NMDAR antibodies (cell-based assay is gold standard)
  • Cell count, protein, glucose
  • IgG index and oligoclonal bands
  • Infectious workup as indicated

Critical interpretation points:

  • If CSF is negative for anti-NMDAR antibodies, the serum +1 result is almost certainly a false positive 5, 7
  • Patients with isolated psychiatric symptoms, positive serum only, and negative CSF typically improve with psychiatric care alone and do not require immunotherapy 7

Step 3: Risk-Stratify Based on Results

If CSF is positive:

  • Diagnosis of anti-NMDAR encephalitis is confirmed
  • Initiate first-line immunotherapy immediately without waiting for tumor screening results 6
  • First-line: High-dose IV corticosteroids, IVIG, or plasma exchange (often combined, with plasma exchange preceding IVIG) 6
  • Screen for ovarian teratoma in young/middle-aged females (transvaginal/transabdominal ultrasound) or testicular teratoma in males 1
  • Broader tumor screening: CT chest/abdomen/pelvis, mammogram in women, consider whole-body FDG-PET if initial screening negative 1

If CSF is negative:

  • The serum +1 result is clinically irrelevant 1
  • Pursue alternative diagnoses
  • Provide standard psychiatric or neurologic care as clinically indicated
  • Do NOT initiate immunotherapy based on serum alone

Step 4: Second-Line Therapy if Needed

For CSF-positive patients not responding to first-line treatment within 2-4 weeks 6:

  • Rituximab, cyclophosphamide, or both
  • Continue tumor surveillance if not yet identified

Common Pitfalls to Avoid

Do not treat based on serum alone: This is the most critical error. Serum antibodies without CSF confirmation lead to unnecessary immunosuppression in patients who do not have anti-NMDAR encephalitis 2, 4, 7.

Do not order testing in low pre-test probability scenarios: Testing patients without compatible clinical features generates false positives that create diagnostic confusion 2. The +1 result likely represents this scenario.

Do not use commercial kits in non-reference labs as definitive: These demonstrate lower sensitivity, particularly for serum 4. If clinical suspicion remains high despite negative commercial testing, send to a reference laboratory.

Do not delay CSF testing: Waiting for serum results to "pan out" wastes critical treatment time if true encephalitis is present 6.

Antibody Titer Significance

Higher titers correlate with worse outcomes and presence of teratoma 3. A +1 (very low titer) in serum makes true disease even less likely. During treatment and recovery, antibody titers decrease but often remain detectable—this does not indicate treatment failure 3.

Bottom line: A serum-only low-positive result (+1) without CSF confirmation and without compatible clinical features should be disregarded as a false positive. Obtain CSF testing if clinical suspicion exists; otherwise, pursue alternative diagnoses.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.